{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T04:02:45Z","timestamp":1745899365732,"version":"3.40.4"},"reference-count":50,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd016090","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T10:48:14Z","timestamp":1745837294000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tyrosine kinase inhibitor maintenance therapy after stem cell transplantation for FLT3-mutated acute myeloid leukemia"],"prefix":"10.1002","volume":"2025","author":[{"given":"Po-Huang","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine; Tri-Service General Hospital, National Defense Medical Center; Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Jie","family":"Jhou","sequence":"additional","affiliation":[{"name":"Department of Neurology; Changhua Christian Hospital; Changhua Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cho-Hao","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine; Tri-Service General Hospital, National Defense Medical Center; Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"issue":"23","key":"10.1002\/14651858.CD016090-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD016090-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s00277-017-3150-3","article-title":"Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)","volume":"96","author":"Nagel","year":"2017","journal-title":"Annual Hematology"},{"key":"10.1002\/14651858.CD016090-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41375-019-0694-3","article-title":"FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions","volume":"34","author":"Antar","year":"2020","journal-title":"Leukemia"},{"issue":"12","key":"10.1002\/14651858.CD016090-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1182\/blood.V96.12.3907","article-title":"Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways","volume":"96","author":"Mizuki","year":"2000","journal-title":"Blood"},{"issue":"12","key":"10.1002\/14651858.CD016090-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD016090-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3324\/haematol.2019.243410","article-title":"Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"105","author":"Bazarbachi","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"10.1002\/14651858.CD016090-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/bmt.2015.170","article-title":"FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML","volume":"51","author":"Song","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1002\/14651858.CD016090-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jamaoncol.2018.2091","article-title":"Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse","volume":"4","author":"Kharfan-Dabaja","year":"2018","journal-title":"JAMA Oncology"},{"key":"10.1002\/14651858.CD016090-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"10.1002\/14651858.CD016090-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"664","DOI":"10.3324\/haematol.2019.240747","article-title":"Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia","volume":"106","author":"Burchert","year":"2021","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD016090-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.lrr.2018.06.003","article-title":"The role of FLT3 inhibitors as maintenance therapy following hematopoietic stem cell transplant","volume":"10","author":"Li","year":"2018","journal-title":"Leukemia Research Report"},{"issue":"5","key":"10.1002\/14651858.CD016090-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD016090-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(15)00362-9","article-title":"Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial","volume":"16","author":"R\u00f6llig","year":"2015","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD016090-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.2012.46.4990","article-title":"Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial","volume":"31","author":"Serve","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"408","key":"10.1002\/14651858.CD016090-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"QuANTUM-First Study Group. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD016090-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD016090-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2023-185951","article-title":"Real world experience of FLT3-inhibitor post-transplant maintenance with sorafenib demonstrating superior overall- and relapse-free survival following allogeneic hematopoietic stem cell transplantation in FLT3-ITD mutated acute myeloid leukemia","volume":"142","author":"Eissa","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD016090-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/17474086.2021.1969911","article-title":"Safety of FLT3 inhibitors in patients with acute myeloid leukemia","volume":"14","author":"Cerchione","year":"2021","journal-title":"Expert Review of Hematology"},{"issue":"2","key":"10.1002\/14651858.CD016090-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1517\/14740330903510608","article-title":"Toxicity of sorafenib: clinical and molecular aspects","volume":"9","author":"Blanchet","year":"2010","journal-title":"Expert Opinion on Drug Safety"},{"issue":"1","key":"10.1002\/14651858.CD016090-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood-2013-10-529313","article-title":"Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants","volume":"123","author":"Galanis","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD016090-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"6877","DOI":"10.1002\/cam4.5480","article-title":"FLT3 inhibitors as maintenance therapy post allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with FLT3 mutations: a meta-analysis","volume":"12","author":"Fei","year":"2023","journal-title":"Cancer Medicine"},{"issue":"3","key":"10.1002\/14651858.CD016090-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1365-2133.2007.08357.x","article-title":"Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy","volume":"158","author":"Yang","year":"2008","journal-title":"British Journal of Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD016090-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2011.36.9868","article-title":"Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis","volume":"30","author":"Brunet","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD016090-BIB0024|cit24","first-page":"149","article-title":"Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia","volume":"4","author":"Jan","year":"2012","journal-title":"Scientific Translational Medicine"},{"issue":"10","key":"10.1002\/14651858.CD016090-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.3390\/ijms19103198","article-title":"Targeting oncogenic signaling in mutant FLT3 acute myeloid leukemia: the path to least resistance","volume":"19","author":"Staudt","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"issue":"5","key":"10.1002\/14651858.CD016090-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/bjh.12299","article-title":"Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD","volume":"161","author":"Takahashi","year":"2013","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD016090-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm.4484","article-title":"Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells","volume":"24","author":"Mathew","year":"2018","journal-title":"Nature Medicine"},{"issue":"17","key":"10.1002\/14651858.CD016090-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.3390\/cancers14174315","article-title":"Overcoming resistance: FLT3 inhibitors past, present, future and the challenge of cure","volume":"14","author":"Capelli","year":"2022","journal-title":"Cancers"},{"key":"10.1002\/14651858.CD016090-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12185-022-03416-7","article-title":"Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment","volume":"116","author":"Kreidieh","year":"2022","journal-title":"International Journal of Hematology"},{"issue":"26","key":"10.1002\/14651858.CD016090-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD016090-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.3390\/ijms22115873","article-title":"FLT3 tyrosine kinase inhibitors for the treatment of fit and unfit patients with FLT3-mutated AML: a systematic review","volume":"22","author":"Loschi","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1002\/14651858.CD016090-BIB0032|cit32","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"issue":"12","key":"10.1002\/14651858.CD016090-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"key":"10.1002\/14651858.CD016090-BIB0034|cit34","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"issue":"24","key":"10.1002\/14651858.CD016090-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD016090-BIB0036|cit36","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023. Available from www.training.cochrane.org\/handbook 2023"},{"key":"10.1002\/14651858.CD016090-BIB0037|cit37","unstructured":"EndNote The EndNote Team Clarivate 2013"},{"key":"10.1002\/14651858.CD016090-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2020","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016090-BIB0039|cit39","unstructured":"Li T Higgins JPT Deeks JJ Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016090-BIB0040|cit40","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"key":"10.1002\/14651858.CD016090-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016090-BIB0042|cit42","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"issue":"8","key":"10.1002\/14651858.CD016090-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"7","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"7109","key":"10.1002\/14651858.CD016090-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"414","key":"10.1002\/14651858.CD016090-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD016090-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jama.2013.285063","article-title":"How to use a subgroup analysis: users' guide to the medical literature","volume":"311","author":"Sun","year":"2014","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD016090-BIB0047|cit47","unstructured":"Welch VA Petkovic J Jull J Hartling L Klassen T Kristjansson E Chapter 16: Equity and specific populations. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016090-BIB0048|cit48","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2024"},{"key":"10.1002\/14651858.CD016090-BIB0049|cit49","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"},{"issue":"1","key":"10.1002\/14651858.CD016090-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","article-title":"NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021: Featured Updates to the NCCN Guidelines","volume":"19","author":"Pollyea","year":"2021","journal-title":"Journal of the National Comprehensive Cancer Network"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T10:48:23Z","timestamp":1745837303000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD016090"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd016090","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]}}}